Published in J Clin Pathol on December 01, 2004
The nanomechanical signature of breast cancer. Nat Nanotechnol (2012) 2.89
Robust segmentation of overlapping cells in histopathology specimens using parallel seed detection and repulsive level set. IEEE Trans Biomed Eng (2011) 2.08
Basal-like phenotype is not associated with patient survival in estrogen-receptor-negative breast cancers. Breast Cancer Res (2007) 1.91
The application of JPEG2000 in virtual microscopy. J Digit Imaging (2007) 1.76
Development and evaluation of a virtual microscopy application for automated assessment of Ki-67 expression in breast cancer. BMC Clin Pathol (2011) 1.46
Linking whole-slide microscope images with DICOM by using JPEG2000 interactive protocol. J Digit Imaging (2009) 1.39
Virtual microscopy. J Clin Pathol (2004) 1.24
A European network for virtual microscopy--design, implementation and evaluation of performance. Virchows Arch (2009) 1.21
Web-based virtual microscopy for parasitology: a novel tool for education and quality assurance. PLoS Negl Trop Dis (2008) 1.08
Development and use of a genitourinary pathology digital teaching set for trainee education. J Pathol Inform (2010) 1.06
Grid technology in tissue-based diagnosis: fundamentals and potential developments. Diagn Pathol (2006) 1.04
Traditional microscopy instruction versus process-oriented virtual microscopy instruction: a naturalistic experiment with control group. Diagn Pathol (2011) 0.97
Shifting gears higher--digital slides in graduate education--4 years experience at Semmelweis University. Diagn Pathol (2010) 0.91
SurfaceSlide: a multitouch digital pathology platform. PLoS One (2012) 0.86
[Virtual microscopy and digital pathology]. Pathologe (2006) 0.81
Virtual microscopy system at Chinese medical university: an assisted teaching platform for promoting active learning and problem-solving skills. BMC Med Educ (2014) 0.80
[Cytology in the internet]. Pathologe (2007) 0.79
Anticancer compound ABT-263 accelerates apoptosis in virus-infected cells and imbalances cytokine production and lowers survival rates of infected mice. Cell Death Dis (2013) 0.79
Digital slides and ACGME resident competencies in anatomic pathology: An altered paradigm for acquisition and assessment. J Pathol Inform (2011) 0.78
Extended Field Laser Confocal Microscopy (EFLCM): combining automated Gigapixel image capture with in silico virtual microscopy. BMC Med Imaging (2008) 0.78
More technology, better learning resources, better learning? Lessons from adopting virtual microscopy in undergraduate medical education. Anat Sci Educ (2012) 0.78
Implementation of virtual microscope slides in the annual pathobiology of cancer workshop laboratory. Hum Pathol (2003) 2.01
Automated complete slide digitization: a medium for simultaneous viewing by multiple pathologists. J Pathol (2001) 1.97
Use of virtual microscopy for didactic live-audience presentation in anatomic pathology. Ann Diagn Pathol (2003) 1.83
Digital slide and virtual microscopy based routine and telepathology evaluation of routine gastrointestinal biopsy specimens. J Clin Pathol (2003) 1.69
The virtual case: a new method to completely digitize cytological and histological slides. Virchows Arch (2001) 1.46
Virtual slides: high-quality demand, physical limitations, and affordability. Hum Pathol (2003) 1.42
Application of virtual microscopy in clinical cytopathology. Diagn Cytopathol (2001) 1.41
Web-based pathology education. Arch Pathol Lab Med (1998) 1.24
Using a modified standard microscope to generate virtual slides. Anat Rec B New Anat (2003) 1.24
[A multimedia atlas of skin pathology]. Cesk Patol (2001) 0.94
In vivo amplification of the androgen receptor gene and progression of human prostate cancer. Nat Genet (1995) 6.60
Optimizing comparative genomic hybridization for analysis of DNA sequence copy number changes in solid tumors. Genes Chromosomes Cancer (1994) 5.52
Molecular cytogenetics of primary breast cancer by CGH. Genes Chromosomes Cancer (1998) 4.22
Genetic heterogeneity and clonal evolution underlying development of asynchronous metastasis in human breast cancer. Cancer Res (1997) 4.02
Amplification of HER-2 in gastric carcinoma: association with Topoisomerase IIalpha gene amplification, intestinal type, poor prognosis and sensitivity to trastuzumab. Ann Oncol (2005) 4.00
Androgen receptor gene amplification: a possible molecular mechanism for androgen deprivation therapy failure in prostate cancer. Cancer Res (1997) 3.37
Treatment of severe refractory autoimmune hemolytic anemia in B-cell chronic lymphocytic leukemia with alemtuzumab (humanized CD52 monoclonal antibody). Leukemia (2007) 3.33
Inherited susceptibility to uterine leiomyomas and renal cell cancer. Proc Natl Acad Sci U S A (2001) 3.31
Aggressiveness of screen-detected breast cancers. Lancet (1995) 3.07
Loss of estrogen receptor in recurrent breast cancer is associated with poor response to endocrine therapy. J Clin Oncol (1996) 2.83
Positional cloning of ZNF217 and NABC1: genes amplified at 20q13.2 and overexpressed in breast carcinoma. Proc Natl Acad Sci U S A (1998) 2.80
Extending the phenotype of recurrent rearrangements of 16p11.2: deletions in mentally retarded patients without autism and in normal individuals. Eur J Med Genet (2009) 2.65
Chromogenic in situ hybridization: a practical alternative for fluorescence in situ hybridization to detect HER-2/neu oncogene amplification in archival breast cancer samples. Am J Pathol (2000) 2.41
Chromosomal alterations in 15 breast cancer cell lines by comparative genomic hybridization and spectral karyotyping. Genes Chromosomes Cancer (2000) 2.24
Prognostic significance of HER-2 oncoprotein expression in breast cancer: a 30-year follow-up. J Clin Oncol (1992) 2.10
Estrogen receptor beta is coexpressed with ERalpha and PR and associated with nodal status, grade, and proliferation rate in breast cancer. Am J Pathol (2000) 2.07
Distinct somatic genetic changes associated with tumor progression in carriers of BRCA1 and BRCA2 germ-line mutations. Cancer Res (1997) 2.03
Amplification and deletion of topoisomerase IIalpha associate with ErbB-2 amplification and affect sensitivity to topoisomerase II inhibitor doxorubicin in breast cancer. Am J Pathol (2000) 2.01
Independent amplification and frequent co-amplification of three nonsyntenic regions on the long arm of chromosome 20 in human breast cancer. Cancer Res (1996) 1.89
Characterization of topoisomerase II alpha gene amplification and deletion in breast cancer. Genes Chromosomes Cancer (1999) 1.82
Dual-colour chromogenic in situ hybridization for testing of HER-2 oncogene amplification in archival breast tumours. J Pathol (2006) 1.68
Leucocyte nadir as a marker for chemotherapy efficacy in node-positive breast cancer treated with adjuvant CMF. Br J Cancer (1999) 1.67
Cell death induced by dexamethasone in lymphoid leukemia is mediated through initiation of autophagy. Cell Death Differ (2009) 1.67
Quantitative real-time PCR analysis and microarray-based RNA expression of HER2 in relation to outcome. Ann Oncol (2007) 1.64
Allogeneic induction of the human T cell-instructed monocyte procoagulant response is rapid and is elicited by HLA-DR. J Exp Med (1983) 1.60
Amplification of HER-2/neu and topoisomerase IIalpha in primary and metastatic breast cancer. Cancer Res (2001) 1.60
Optimizing DOP-PCR for universal amplification of small DNA samples in comparative genomic hybridization. Genes Chromosomes Cancer (1997) 1.59
Cytokines, adhesion molecules, and cellular infiltration in nephropathia epidemica kidneys: an immunohistochemical study. Clin Immunol Immunopathol (1996) 1.55
Redo bypass surgery to the infrapopliteal arteries for critical leg ischaemia. Eur J Vasc Endovasc Surg (2001) 1.47
Serum tumour markers CA 15-3, TPA, TPS, hCGbeta and TATI in the monitoring of chemotherapy response in metastatic breast cancer. Scand J Clin Lab Invest (2001) 1.47
Amplification and overexpression of p40 subunit of eukaryotic translation initiation factor 3 in breast and prostate cancer. Am J Pathol (1999) 1.42
Amplification of chromosomal region 20q13 in invasive breast cancer: prognostic implications. Clin Cancer Res (1995) 1.38
Colon interposition for esophageal disease: histologic finding of colonic mucosa after a follow-up of 5 months to 15 years. Am J Gastroenterol (1991) 1.38
Small subgroup of aggressive, highly proliferative prostatic carcinomas defined by p53 accumulation. J Natl Cancer Inst (1992) 1.36
Genetic alterations in lobular breast cancer by comparative genomic hybridization. Int J Cancer (1997) 1.34
Bmi-1 expression predicts prognosis in squamous cell carcinoma of the tongue. Br J Cancer (2010) 1.33
Effect of age on the survival of breast cancer patients. Eur J Cancer (1997) 1.30
Virtual microscopy. J Clin Pathol (2004) 1.24
Reliability of the tissue microarray based FISH for evaluation of the HER-2 oncogene in breast carcinoma. J Clin Pathol (2002) 1.22
Renal biopsy findings and clinicopathologic correlations in nephropathia epidemica. Clin Nephrol (1994) 1.21
Expression of topoisomerase IIalpha is associated with rapid cell proliferation, aneuploidy, and c-erbB2 overexpression in breast cancer. Am J Pathol (1996) 1.17
Ki-67, p53, Er-receptors, ploidy and S-phase as prognostic factors in T1 node negative breast cancer. Acta Oncol (1997) 1.17
Expression of peripheral-type benzodiazepine receptor and diazepam binding inhibitor in human astrocytomas: relationship to cell proliferation. Cancer Res (1995) 1.17
MYB oncogene amplification in hereditary BRCA1 breast cancer. Cancer Res (2000) 1.16
Lumpectomy with or without postoperative radiotherapy for breast cancer with favourable prognostic features: results of a randomized study. Br J Cancer (2001) 1.15
Monocyte procoagulant inducing factor: a lymphokine involved in the T cell-instructed monocyte procoagulant response to antigen. J Immunol (1986) 1.14
Macrophages contain 92-kd gelatinase (MMP-9) at the site of degenerated internal elastic lamina in temporal arteritis. Am J Pathol (1996) 1.13
Low biologic aggressiveness in breast cancer in women using hormone replacement therapy. J Clin Oncol (1998) 1.13
Characterization of chromosomal abnormalities in prostate cancer cell lines by spectral karyotyping. Cytogenet Cell Genet (1999) 1.12
HER-2/neu as a predictive marker in a population of advanced breast cancer patients randomly treated either with single-agent doxorubicin or single-agent docetaxel. Breast Cancer Res Treat (2004) 1.12
Follow-up of patients positive in reticulin and gliadin antibody tests with normal small-bowel biopsy findings. Scand J Gastroenterol (1993) 1.11
Pancreatic acinar ultrastructure in human acute pancreatitis. Virchows Arch A Pathol Anat Histol (1980) 1.10
Genetic changes in intraductal breast cancer detected by comparative genomic hybridization. Am J Pathol (1997) 1.10
HER-2 and topo-isomerase IIalpha as predictive markers in a population of node-positive breast cancer patients randomly treated with adjuvant CMF or epirubicin plus cyclophosphamide. Ann Oncol (2001) 1.07
Chromosomal aberrations in breast cancer: a comparison between cytogenetics and comparative genomic hybridization. Genes Chromosomes Cancer (1999) 1.07
p-53 gene mutations as a predictive marker in a population of advanced breast cancer patients randomly treated with doxorubicin or docetaxel in the context of a phase III clinical trial. Ann Oncol (2007) 1.06
Epithelial and stromal syndecan-1 expression as predictor of outcome in patients with gastric cancer. Int J Cancer (2001) 1.05
Crystal structure of human erythrocyte carbonic anhydrase C. 3. Molecular structure of the enzyme and of one enzyme-inhibitor complex at 5-5 A resolution. J Mol Biol (1967) 1.05
Variability in B-cell antigen expression: implications for the treatment of B-cell lymphomas and leukemias with monoclonal antibodies. Hematol J (2001) 1.05
Claudins 1, 3, 4 and 5 in gastric carcinoma, loss of claudin expression associates with the diffuse subtype. Virchows Arch (2005) 1.04
CA 242, a new tumour marker for pancreatic cancer: a comparison with CA 19-9, CA 50 and CEA. Br J Cancer (1994) 1.03
Epithelial syndecan-1 expression is associated with stage and grade in colorectal cancer. Oncology (2005) 1.03
Colocalization of peptide and glucocorticoid receptor immunoreactivities in rat central amygdaloid nucleus. Neuroendocrinology (1992) 1.03
Patterns of chromosomal imbalances in parathyroid carcinomas. Am J Pathol (2000) 1.02
Artificial neural networks applied to survival prediction in breast cancer. Oncology (1999) 1.02
Membranous location of EGFR immunostaining is associated with good prognosis in renal cell carcinoma. Br J Cancer (2003) 1.02
Improved prognostic impact of S-phase values from paraffin-embedded breast and prostate carcinomas after correcting for nuclear slicing. Cytometry (1991) 1.02
Molecular cytogenetics of human breast cancer. Cold Spring Harb Symp Quant Biol (1994) 1.02
Overexpression of p53 and long-term survival in colon carcinoma. Br J Cancer (1994) 1.01
IgM-associated glomerulonephritis. Nephron (1982) 1.01
Germline BRCA1 and HMLH1 mutations in a family with male and female breast carcinoma. Int J Cancer (2000) 1.01
A regression model for identifying patients at high risk of hypotension, bradycardia and nausea during spinal anesthesia. Acta Anaesthesiol Scand (1992) 1.00
High CIP2A immunoreactivity is an independent prognostic indicator in early-stage tongue cancer. Br J Cancer (2011) 0.99
Stromal cell cathepsin D expression and long-term survival in breast cancer. Br J Cancer (1995) 0.99
Lymphoma in dermatitis herpetiformis: report on four cases. Acta Derm Venereol (1982) 0.99
Steroid receptors and Ki-67 reactivity in ovarian cancer and in normal ovary: correlation with DNA flow cytometry, biochemical receptor assay, and patient survival. J Pathol (1990) 0.99
Prognostic effect of timing of operation in relation to menstrual phase of breast cancer patient--fact or fallacy. Br J Cancer (1995) 0.98
Increased cell proliferation activity and decreased cell death are associated with the emergence of hormone-refractory recurrent prostate cancer. J Pathol (1997) 0.98
Aberrant p53 expression in astrocytic neoplasms of the brain: association with proliferation. Am J Pathol (1993) 0.98
Pre- and postjunctional modulation of cholinergic neuroeffector transmission by adenine nucleotides. Experiments with agonist and antagonist. Acta Physiol Scand (1985) 0.97
Amplification of c-myc oncogene by chromogenic and fluorescence in situ hybridization in archival breast cancer tissue array samples. Lab Invest (2001) 0.97
Expression and prognostic value of transcription factor PROX1 in colorectal cancer. Br J Cancer (2011) 0.96
STn and prognosis in breast cancer. Oncology (2001) 0.95
HER2 oncogene amplification in extramammary Paget's disease. Histopathology (2003) 0.95
Chromosomal rearrangements and oncogene amplification precede aneuploidization in the genetic evolution of breast cancer. Cancer Res (2001) 0.95
Tissue expression of human chorionic gonadotropin beta predicts outcome in colorectal cancer: a comparison with serum expression. Int J Cancer (2001) 0.94
Expression of epidermal growth factor receptor and ERBB2 (HER-2/Neu) oncoprotein in prostatic carcinomas. Mod Pathol (1992) 0.94
Amplification of the epidermal growth factor receptor in astrocytic tumours by chromogenic in situ hybridization: association with clinicopathological features and patient survival. Neuropathol Appl Neurobiol (2006) 0.94
Mapping the amplification of EIF3S3 in breast and prostate cancer. Genes Chromosomes Cancer (2000) 0.93
Sensitive detection of chromosome copy number aberrations in prostate cancer by fluorescence in situ hybridization. Am J Pathol (1994) 0.93